Interesting the timing of this new variant. Perhaps in 2025 leronlimab will be given the green light for resuming trials related to covid.
Until then, Cyrus and board are rightfully focused on other indications. I would hate to see a combination with Pfizer for cancer. They are cleaning house right now just dropping some affiliations for cancer that did not pan out. However, as much as I hate pfizer the fixer, I would take it. It would serve to rectify their horrible reputation and of course serve mankind beneficially. I will cry all the way to the bank.
Our President and board have made great strides in meeting with the fda for the hold and other business. Delays caused as a result of AmarX not forthcoming with timely and correct data. Damages have mounted as a result.
Cyrus said it would not be soon for the hold to be lifted as he knows the pace of the fda.
So all of their concerns have been addressed and now we wait on the FootDraggingAgency.
Not surprising would be an announcement SOON and I think it will have to do with the affilation with the Oregon State lab. Also, very likely an update on Nash, or our (Oncology) Fast Track designation with TNeg Breast Cancer, plus the focus on other HIV indications. So the company has a plate full of work going on.
A little basic research is all it takes to know a lot of activity is going on with the company. That voluntary removal of the BLA was a shrewd bold move by Cyrus. It shows the exacerbated damages by CRO AmarX. It's going to be a really good show! $CYDY$
Yes sir, I am very bullish on our company. Leronlimab is that good. Know what you own. $CYDY$
Bullish
AI
Market Data 
Markets 
